Achmea Investment Management B.V. Grows Stake in IDEXX Laboratories, Inc. $IDXX

Achmea Investment Management B.V. grew its stake in shares of IDEXX Laboratories, Inc. (NASDAQ:IDXX) by 319.9% in the 3rd quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 17,769 shares of the company’s stock after acquiring an additional 13,537 shares during the quarter. Achmea Investment Management B.V.’s holdings in IDEXX Laboratories were worth $11,353,000 as of its most recent SEC filing.

Several other large investors have also recently modified their holdings of IDXX. Vanguard Group Inc. boosted its stake in IDEXX Laboratories by 0.9% in the 3rd quarter. Vanguard Group Inc. now owns 9,962,025 shares of the company’s stock worth $6,364,638,000 after purchasing an additional 86,040 shares in the last quarter. Bank of New York Mellon Corp increased its stake in IDEXX Laboratories by 41.7% during the 3rd quarter. Bank of New York Mellon Corp now owns 2,056,680 shares of the company’s stock valued at $1,313,992,000 after purchasing an additional 605,290 shares in the last quarter. Invesco Ltd. raised its holdings in IDEXX Laboratories by 14.0% in the third quarter. Invesco Ltd. now owns 1,320,263 shares of the company’s stock worth $843,503,000 after buying an additional 161,782 shares during the last quarter. Principal Financial Group Inc. lifted its stake in shares of IDEXX Laboratories by 16.7% in the third quarter. Principal Financial Group Inc. now owns 1,315,722 shares of the company’s stock worth $840,638,000 after buying an additional 187,967 shares in the last quarter. Finally, JPMorgan Chase & Co. lifted its stake in shares of IDEXX Laboratories by 60.0% in the third quarter. JPMorgan Chase & Co. now owns 869,930 shares of the company’s stock worth $555,802,000 after buying an additional 326,348 shares in the last quarter. Hedge funds and other institutional investors own 87.84% of the company’s stock.

Analysts Set New Price Targets

Several equities research analysts recently weighed in on the stock. Piper Sandler reduced their price target on shares of IDEXX Laboratories from $775.00 to $750.00 and set a “neutral” rating for the company in a research report on Monday, February 9th. Barclays lowered their price objective on IDEXX Laboratories from $850.00 to $800.00 and set an “overweight” rating on the stock in a research report on Thursday, February 5th. Weiss Ratings lowered IDEXX Laboratories from a “buy (b-)” rating to a “hold (c+)” rating in a report on Thursday, January 29th. Wall Street Zen cut IDEXX Laboratories from a “strong-buy” rating to a “buy” rating in a research note on Saturday, February 28th. Finally, UBS Group lowered their price target on IDEXX Laboratories from $750.00 to $730.00 and set a “neutral” rating on the stock in a report on Tuesday, February 3rd. Seven analysts have rated the stock with a Buy rating and three have given a Hold rating to the company’s stock. According to data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and a consensus target price of $783.33.

Insider Activity

In other IDEXX Laboratories news, Director Sophie V. Vandebroek sold 1,464 shares of the firm’s stock in a transaction that occurred on Tuesday, February 17th. The shares were sold at an average price of $628.62, for a total transaction of $920,299.68. Following the sale, the director owned 648 shares in the company, valued at approximately $407,345.76. This trade represents a 69.32% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, CEO Jonathan Jay Mazelsky sold 23,326 shares of IDEXX Laboratories stock in a transaction that occurred on Thursday, February 26th. The shares were sold at an average price of $657.55, for a total transaction of $15,338,011.30. Following the transaction, the chief executive officer directly owned 83,606 shares in the company, valued at $54,975,125.30. This represents a 21.81% decrease in their position. The SEC filing for this sale provides additional information. Over the last quarter, insiders sold 45,957 shares of company stock worth $29,862,109. 0.98% of the stock is currently owned by corporate insiders.

IDEXX Laboratories Trading Down 1.7%

NASDAQ:IDXX opened at $577.12 on Thursday. IDEXX Laboratories, Inc. has a one year low of $356.14 and a one year high of $769.98. The business has a fifty day moving average price of $651.11 and a 200-day moving average price of $665.40. The firm has a market capitalization of $45.89 billion, a price-to-earnings ratio of 44.16, a price-to-earnings-growth ratio of 3.56 and a beta of 1.66. The company has a debt-to-equity ratio of 0.23, a current ratio of 1.23 and a quick ratio of 0.90.

IDEXX Laboratories (NASDAQ:IDXX) last released its earnings results on Monday, February 2nd. The company reported $2.92 earnings per share for the quarter, missing the consensus estimate of $2.93 by ($0.01). IDEXX Laboratories had a net margin of 24.62% and a return on equity of 69.78%. The company had revenue of $1.09 billion for the quarter, compared to analysts’ expectations of $1.07 billion. During the same quarter last year, the firm posted $2.53 earnings per share. IDEXX Laboratories’s revenue for the quarter was up 14.3% on a year-over-year basis. IDEXX Laboratories has set its FY 2026 guidance at 14.290-14.800 EPS. Sell-side analysts forecast that IDEXX Laboratories, Inc. will post 11.93 EPS for the current year.

IDEXX Laboratories Company Profile

IDEXX Laboratories, Inc (NASDAQ: IDXX) is a global developer, manufacturer and provider of diagnostic products and services primarily for the animal health, water testing and food safety markets. Headquartered in Westbrook, Maine, the company supplies in-clinic diagnostic instruments, consumables, reference laboratory testing and practice-management tools that support veterinarians, livestock and dairy producers, and utilities and food producers worldwide.

IDEXX’s product portfolio includes point-of-care tests and immunoassays designed for rapid diagnosis in veterinary clinics, in-clinic chemistry and hematology analyzers, automated urinalysis systems, and digital diagnostic solutions.